undamentalytics Newsletter
Sign in

Neurocrine Biosciences Inc cash flow statement

In fiscal 2025, Neurocrine Biosciences Inc's operations generated $783m of cash; it spent $34.0m on capital projects, leaving free cash flow of $749m. It returned $168m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−5350−1−35−30−47−38−106−941011472292573393905957831,066
Depreciation and amortisation311111112479111518242631
Stock-based pay63357102828435875100134173194196218235
Capital spending001112247251511231728383426
Free cash flow−5350−1−36−30−49−40−110−101771322182333233625577491,040
Free cash flow after stock pay−5946−4−42−37−59−68−139−144195711899150167362531805
Share buybacks—————————————00300168158
Shares issued10210845139277214303229284565122129171

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BMRN vs NBIXARGX vs NBIXBNTX vs NBIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Neurocrine Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neurocrine Biosciences Inc.